tradingkey.logo

Vivos Therapeutics Inc

VVOS
View Detailed Chart

3.440USD

+0.100+2.99%
Close 09/19, 16:00ETQuotes delayed by 15 min
25.20MMarket Cap
LossP/E TTM

Vivos Therapeutics Inc

3.440

+0.100+2.99%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.99%

5 Days

-0.86%

1 Month

-19.44%

6 Months

-2.55%

Year to Date

-19.81%

1 Year

+6.83%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
127 / 207
Overall Ranking
307 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.250
Target Price
+57.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
Growing
The company is in a growing phase, with the latest annual income totaling USD 15.03M.
Undervalued
The company’s latest PE is -2.95, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.22M shares, increasing 29.81% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 42.63K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
Ticker SymbolVVOS
CompanyVivos Therapeutics Inc
CEOMr. R. Kirk Huntsman
Websitehttps://vivos.com/
KeyAI